Parliament Workbench
Data: Votes to 12 Nov 2026

Vote · 20 Feb 2013

Health

Amendment Motion S4M-05654.2 Lodged by Alex Neil SNP
Carried by 65
67 For 2 Against 46 Abstained 13 Did not vote

What this amendment would do

This vote was on an SNP amendment (S4M-05654.2) to the Conservatives’ motion (S4M-05654). It was agreed, so the motion’s final vote was on the wording as amended, with words from the original removed.

If agreed, the motion would read:

That the Parliament recognises the need to facilitate access to new medicines that are not routinely available or have not been approved by the Scottish Medicines Consortium (SMC); notes that the current arrangements
129 words removed by S4M-05654.2potentially deny NHS patients in Scotland access to some life-enhancing and life-extending drugs that are available to NHS patients in England, particularly for the treatment of cancer; accepts that, while the routine approval of individual drugs is rightly a matter for the SMC, it is equally the case that it is a decision for ministers to allocate appropriate alternative funding for medicines that are not routinely available in Scotland; notes concern at the slow uptake of new medicines in Scotland; believes that such problems need to be addressed to promote Scotland as a centre for medical innovation and research to benefit patients in the future, and calls on the Scottish Government to come forward with funding to afford access to new medicines in Scotland for cancer patients and others.
S4M-05654.2 SNP for all aspects of access to new medicines are subject to an ongoing review; welcomes the introduction of the £21 million Rare Conditions Medicines Fund as an interim measure in response to advice by Professor Charles Swainson, who is undertaking the review of individual patient treatment request processes; accepts that routine approval of individual drugs is rightly a matter for the SMC and that, should the review highlight areas where these processes can be improved, these should be enacted quickly, and believes that the actual benefit to the patient and their quality of life must be the key consideration in determining the use of any new treatment or medicine and that the voices of patients and clinical experts must be heard in the assessment process.

Worked out by this site by applying the amendment to the motion as lodged. It is not an official text.

The amendment as lodged

leave out from “potentially” to end and insert "for all aspects of access to new medicines are subject to an ongoing review; welcomes the introduction of the £21 million Rare Conditions Medicines Fund as an interim measure in response to advice by Professor Charles Swainson, who is undertaking the review of individual patient treatment request processes; accepts that routine approval of individual drugs is rightly a matter for the SMC and that, should the review highlight areas where these processes can be improved, these should be enacted quickly, and believes that the actual benefit to the patient and their quality of life must be the key consideration in determining the use of any new treatment or medicine and that the voices of patients and clinical experts must be heard in the assessment process."

All amendments to S4M-05654

  1. S4M-05654.2 SNP Alex Neil Agreed vote, 67–2
  2. S4M-05654.1 Labour Jackie Baillie Defeated vote, 54–61

How the parties split

2 MSPs voted against their party
PartySplitForAgainstAbst.AbsentMajority
SNP 60 0 0 5 ✓ For united
Lab 0 0 34 3 – Abstained united
Con 0 2 12 1 – Abstained split
LD 4 0 0 1 ✓ For united
Green 2 0 0 0 ✓ For united
Ind 1 0 0 3 n/a

Party is the MSP's party on the day of the vote. Majority is how most of the party's voting MSPs voted.

Every MSP

128 MSPs

For (67)

Against (2)

Abstained (46)

Did not vote (13)

Con 1